PMID- 33775925
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20221221
IS  - 1878-5832 (Electronic)
IS  - 1359-6446 (Print)
IS  - 1359-6446 (Linking)
VI  - 26
IP  - 8
DP  - 2021 Aug
TI  - Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in 
      SARS-CoV-2.
PG  - 2036-2044
LID - S1359-6446(21)00149-5 [pii]
LID - 10.1016/j.drudis.2021.03.013 [doi]
AB  - Aging and pre-existing conditions in older patients increase severe acute 
      respiratory syndrome coronavirus 2 (SARS-CoV-2) severity and its complications, 
      although the causes remain unclear. Apart from acute pulmonary syndrome, 
      Coronavirus 2019 (COVID-19) can increasingly induce chronic conditions. 
      Importantly, SARS-CoV-2 triggers de novo type 2 diabetes mellitus (T2DM) linked 
      to age-associated cardiovascular disease (CVD), cancers, and neurodegeneration. 
      Mechanistically, SARS-CoV-2 induces inflammation, possibly through 
      damage-associated molecular pattern (DAMP) signaling and 'cytokine storm,' 
      causing insulin resistance and the adiponectin (APN) paradox, a phenomenon 
      linking metabolic dysfunction to chronic disease. Accordingly, preventing the APN 
      paradox by suppressing APN-related inflammatory signaling might prove beneficial. 
      A better understanding could uncover novel therapies for SARS-CoV-2 and its 
      chronic disorders.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Ho, Gilbert
AU  - Ho G
AD  - PCND Neuroscience Research Institute, Poway, CA, USA.
FAU - Ali, Alysha
AU  - Ali A
AD  - PCND Neuroscience Research Institute, Poway, CA, USA.
FAU - Takamatsu, Yoshiki
AU  - Takamatsu Y
AD  - Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, 
      Tokyo, Japan.
FAU - Wada, Ryoko
AU  - Wada R
AD  - Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, 
      Tokyo, Japan.
FAU - Masliah, Eliezer
AU  - Masliah E
AD  - Division of Neurosciences, National Institute on Aging, National Institutes of 
      Health, Bethesda, MD, USA.
FAU - Hashimoto, Makoto
AU  - Hashimoto M
AD  - Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, 
      Tokyo, Japan. Electronic address: hashimoto-mk@igakuken.or.jp.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210326
PL  - England
TA  - Drug Discov Today
JT  - Drug discovery today
JID - 9604391
RN  - 0 (Adiponectin)
SB  - IM
MH  - Adiponectin/*metabolism
MH  - Aging/*physiology
MH  - *COVID-19/immunology/metabolism
MH  - Chronic Disease
MH  - Diabetes Mellitus, Type 2/*immunology
MH  - Humans
MH  - Inflammation/*metabolism
MH  - Paracrine Communication/physiology
MH  - *SARS-CoV-2/pathogenicity/physiology
PMC - PMC7997138
OTO - NOTNLM
OT  - Adiponectin paradox
OT  - Antagonistic pleiotropy
OT  - COVID-19
OT  - Diabetes mellitus
OT  - Inflammation
OT  - SARS-CoV-2
COIS- Declaration of interests The first author, Dr. Gilbert Ho, has previously served 
      on an Advisory Board for Biogen, Inc. The remaining authors declare no known 
      competing financial interests that might influence this paper.
EDAT- 2021/03/30 06:00
MHDA- 2021/09/09 06:00
PMCR- 2021/03/26
CRDT- 2021/03/29 05:58
PHST- 2020/11/16 00:00 [received]
PHST- 2021/02/22 00:00 [revised]
PHST- 2021/03/16 00:00 [accepted]
PHST- 2021/03/30 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
PHST- 2021/03/29 05:58 [entrez]
PHST- 2021/03/26 00:00 [pmc-release]
AID - S1359-6446(21)00149-5 [pii]
AID - 10.1016/j.drudis.2021.03.013 [doi]
PST - ppublish
SO  - Drug Discov Today. 2021 Aug;26(8):2036-2044. doi: 10.1016/j.drudis.2021.03.013. 
      Epub 2021 Mar 26.